Identification of a new hormone-binding site on the surface of thyroid hormone receptor by Souza, P. C. T. et al.
  Universidade de São Paulo
 
2014-04
 
Identification of a new hormone-binding site on
the surface of thyroid hormone receptor
 
 
Molecular Endocrinology, Chevy Chase : Endocrine Society, v. 28, n. 4, p. 534-545, Apr. 2014
http://www.producao.usp.br/handle/BDPI/50741
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Física e Ciência Interdisciplinar - IFSC/FCI Artigos e Materiais de Revistas Científicas - IFSC/FCI
Identification of a New Hormone-Binding Site on the
Surface of Thyroid Hormone Receptor
P.C.T. Souza,* A.C. Puhl,* L. Martínez, R. Aparício, A.S. Nascimento,
A.C.M. Figueira, P. Nguyen, P. Webb, M.S Skaf, and I. Polikarpov
Institute of Chemistry (P.C.T.S., L.M., R.A., M.S.S.), State University of Campinas-UNICAMP, Campinas,
Sao Paulo, Brazil; Institute of Physics of São Carlos (A.C.P., A.S.N., P.W., I.P.), University of São Paulo-
USP, São Carlos, Sao Paulo, Brazil; National Laboratory of Biosciences (A.C.M.F.), CNPEM, Campinas,
Sao Paulo, Brazil; University of California Medical Center (P.N.), Diabetes Center, San Francisco,
California; and Genomic Medicine (P.W.), Houston Methodist Research Institute, Houston, Texas
Thyroid hormone receptors (TRs) are members of the nuclear receptor superfamily of ligand-
activated transcription factors involved in cell differentiation, growth, and homeostasis. Al-
though X-ray structures of many nuclear receptor ligand-binding domains (LBDs) reveal that
the ligand binds within the hydrophobic core of the ligand-binding pocket, a few studies
suggest the possibility of ligands binding to other sites. Here, we report a new x-ray crystal-
lographic structure of TR-LBD that shows a second binding site for T3 and T4 located between
H9, H10, and H11 of the TR LBD surface. Statistical multiple sequence analysis, site-directed mu-
tagenesis, and cell transactivation assays indicate that residues of the second binding site could be
important for the TR function. We also conducted molecular dynamics simulations to investigate
ligandmobility and ligand-protein interaction for T3 andT4 bound to this newTR surface-binding site.
Extensive molecular dynamics simulations designed to compute ligand-protein dissociation constant
indicate that the binding affinities to this surface site are of the order of the plasma and intracellular
concentrations of the thyroid hormones, suggesting that ligands may bind to this new binding site
under physiological conditions. Therefore, the secondbinding site could be useful as a new target site
for drug design and could modulate selectively TR functions. (Molecular Endocrinology 28: 534–545,
2014)
Thyroid hormone receptors (TRs) are members of thenuclear receptor (NR) superfamily of ligand-activated
transcription factors that include the steroid, vitamin D,
and retinoic acid receptors as well as “orphan” receptors
for which there are no known ligand or function (1).
Members of this class of proteins display a conserved
structural organization consisting of anN-terminal trans-
activation domain (activation function [AF]-1), a highly
conserved DNA-binding domain, and ligand-binding do-
main (LBD) in the carboxyl terminus. The LBDs are re-
quired for nuclear localization and homo- and/or het-
erodimerization and also contain a ligand-activated
transactivation function (AF-2) that mediates the ex-
change of corepressor for coactivator (2). TRs are in-
volved in cell differentiation, growth, and homeostasis
(1). There are 2 TR subtypes, TR and TR, which con-
tain highly homologous DNA-binding domain and LBD
sequences (3). The ligand-binding pockets (LBPs) of both
subtypes differ only by a single amino acid residue
(Ser277-TR and Asn331-TR) (4). Although the main
active natural TR ligand is T3, the parental form of the
hormone, T4, can also bind TRs with lower affinity than
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T3 and, because the total serum T4 is 40-fold higher than
T3 (1), there have been suggestions that T4 could modu-
late TR activity (5). TR is found predominantly in the
liver, being involvedwith regulation ofmetabolic rate and
hepatic cholesterol metabolism, whereas TR is found
particularly in the heart and plays a major role in regula-
tion of heart rate (6, 7). Selective TR1 modulators in-
crease metabolism, improve lipid balance, and prevent
deleterious effects on the heart. This class of compounds
has been considered very useful in the treatment of obesity
and hypercholesterolemia, and many efforts have been
devoted to find a good selective modulator molecule
(8–11).
Like other NR family members, TR LBDs are folded
into 3 layers of -helices that form the hydrophobic core
of the molecule, where the ligand is buried. The TR LBD
changes conformation upon agonist binding. This confor-
mational alteration results in a folding pattern consistent
with various members of the nuclear receptor superfam-
ily, suggesting a similarity between NR LBD ligand-bind-
ing mechanisms (12). The ligand induces tight packing of
the LBD C-terminal helix 12 (H12) against the body of
the receptor (12, 13). Molecular dynamics (MD) simula-
tions and new experimental results have expanded this
view, showing that there may be multiple pathways of
ligand entry and exit (14–21).
H12 contributes to ligand binding when it is stabilized
in active conformation, by forming additional ligand-pro-
tein and intraprotein interactions (22). The repositioning
of H12 causes major rearrangements of H11, loop H11–
H12, and the connection between H1 and H3 occur. This
rearrangement of H12 induces formation of coactivator-
binding site motif LXXLL on the liganded NR surface
(residues in helices H3, H4, H5, and H12 itself) that gen-
erates the transcriptional activity of the AF-2 domain of
nuclear receptors, thereby influencing gene expression
(23). Thus, this ligand-regulated protein-protein interac-
tion is critical to mediate transcriptional activation, and
helix H12 is a crucial component of the NR LBD because
it controls agonist/antagonist properties of NRs (24, 25).
A recent study demonstrated that apo-TRH12 in inactive
(and antagonist) conformation is docked in the C-termi-
nal part of H3, blocking coactivator and corepressor in-
terface and suggesting a new mechanism of self-inactiva-
tion for TR (26).
Although X-ray structures of many NR-LBDs reveal
that the ligand binds within the hydrophobic core of the
domain, some other binding sites have been observed for
small molecules. For example, it was shown that the es-
trogen antagonist 4-hydroxytamoxifen (HT), in addition
to occupying the core binding pocket within the LBD of
estrogen receptor (ER) , could also bind to a second site
on its surface. This crystal structure revealed oneHTmol-
ecule bound to the consensus LBP and another bound to
a site that overlaps with the hydrophobic groove of the
coactivator recognition surface (27). The second binding
site for HTwas previously reported in studies of sedimen-
tation patterns. It was demonstrated that, despite the re-
ceptor’s high affinity forHT, the total binding forHTwas
nearly twice the one of estradiol (28). It was proposed that
that the primary, high-affinity site was responsible for
agonist activity of the antiestrogen, whereas the second-
ary, low-affinity site was responsible for antagonist activ-
ity (29). A noncanonical binding pocket was also ob-
served for androgen receptor (AR) and termed BF3
(30–32). At least 3 different ligands were identified with
the ability to bind to this site and weaken coactivator
interaction, thus functioning as AR inhibitors with de-
creased capacity of antiandrogen resistance development
(32). Curiously, BF3 is located in a different region of AR
LBD, next to the AF-2 region, but without overlap with
the coregulators groove (30).
Another example is the alternative ligand-binding site
of the vitamin D receptor (VDR), identified by computa-
tional modeling. Data obtained from docking experi-
ments generated a receptor conformational ensemble
model that could explain how VDR and possibly ER can
have genomic and nongenomic functions. The new alter-
native site partially overlaps with the canonical LBP, not
allowing 2 ligands simultaneously associated with VDR
(33). For peroxisome proliferator-activated receptors
(PPARs), the presence of more than one ligand bound to
the LBD has already been shown by X-ray crystallogra-
phy studies (34–37). The additional ligands bind cooper-
atively in the large LBP of PPARs. An exception is PPAR
associated with ajulemic acid. The crystallographic struc-
ture of this complex shows 2 molecules of this ligand
bound to LBD, one being anchored to the coregulators
interaction groove (38), such as the second HT molecule
bound to ER (27). The same region has been successfully
used for the design of irreversible TR antagonists
(39–41).
In the present study, we used X-ray crystallography to
identify a new second binding site for T3 and T4 within
the LBDof TR. T3 andT4 associate with a secondary site
located between H9, H10, and H11. The main interac-
tions between the second T3/T4 and the LBD are polar
contacts. H12 did not alter its position because of the
presence of a second hormone molecule. Statistical mul-
tiple sequence analysis indicates coupling between amino
acid residues of the first, internal hormone-binding site
and the second, surface-binding site. We also conducted
extensive MD simulations that enabled us to investigate
the mobility, interaction energies, and the binding modes
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of the ligands in the surface binding site and to compute
an estimate of the binding free energy. Furthermore, we
probed amino acid residues of the new ligand-binding site
using site-directed mutagenesis and functional assays.
Collectively, these results indicate that the second binding
site of TR should exist under physiological conditions and
might be relevant for its function.
Materials and Methods
Expression and purification
The plasmid PET28a() (Novagen) encoding a human
TR1 LBD construct fused in frame to the C terminus of a
polyhistidine (His) tag was expressed in Escherichia coli strain
B834. The protein was expressed and purified according to pre-
vious studies (42). Proteins were resuspended in a solution of
600 mM NaCl and 3 mM dithiothreitol and further concen-
trated to 10 mg ml1. The protein content and purity of all
chromatographic fractions were analyzed by Coomassie Blue-
stained SDS-PAGE. Protein concentrations were determined us-
ing the Bradford dye assay (Bio-Rad Laboratories) using BSA as
standard, and the average yield of the protein was about 6 mg
per liter of culture.
Crystallization, data collection, and structure
determination
Crystallization screens were performed according to previ-
ous studies (42). In each trial, a hanging drop of 1 L of hTR
LBD solution containing 10 molar excess of either T3 or T4
was mixed with 1 L precipitant solution and equilibrated
against a reservoir containing 500mL precipitant solution. Suit-
able crystals were grown within 1 day with 0.1 M sodium ca-
codylate (pH 6.5), 1.4 M sodium acetate. Further optimization
led to X-ray diffraction quality crystals of hTR grown in 1.0M
sodium cacodylate and 0.1 M sodium acetate threehydrate (pH
7.2) within 24 hours at 291 K. The crystals grew in orthorhom-
bic P212121 space group. Before data collection, crystals were
soaked in cryoprotectant solutions containing 1.0 M NaCac,
0.1 M NaH3OAc (pH 7.2) and 20% (vol/vol) ethylene glycol
and rapidly cooled in a gaseous nitrogen stream at 100 K. X-ray
diffraction experiments were performed with a MAR research
MAR345dtb image-plate detector mounted on a Rigaku UltraX
18 rotating-anode X-ray generator providing Cu K radiation
operated at 50 kV and 100 mA and equipped with Osmic con-
focal Max-Flux optics. The data sets were reduced, merged,
integrated, and scaled using DENZO and SCALEPACK soft-
wares (43).
The structures were determined by molecular replacement
using AMORE. The TR LBDT3 (PDB code: 1BSX) structure
was used as a model for molecular replacement (44). For the
refinement cycles and model building, we employed PHENIX
(45), REFMAC5 (46), and COOT (47).
Statistical coupling analysis (SCA)
SCA was performed with a multiple sequence alignment of
NR-LBDs from several species to analyze site conservation
(Gstat) and statistical coupling (Gstat) parameters of the sec-
ond binding site. The multiple sequence alignment was down-
loaded from the Pfam server (http://www.sanger.ac.uk/Soft-
ware/Pfam/) and edited with the Jalview program (48) to
remove gaps and redundancy at a cut-off of 95%, remaining in
the final alignment 1297 protein sequences. The SCA was con-
ducted as previously described (49, 50). The matrix containing
all performed perturbations was subjected to successive rounds
of clustering rows and columns with similar Gstat distribu-
tion using the software package MATLAB (The Mathworks,
Inc) and after each cycle, positions with weak signals were dis-
carded. All the results shown in this work are reported on hu-
man TR (PDB code 2H79).
Site-directed mutagenesis and cell transactivation
assays
The residues of the second binding site were submitted to
site-directed mutagenesis using QuikChange site-directed mu-
tagenesis kit according to themanufacturer’s instructions (Strat-
agene). Single-point mutations were introduced (D382R,
E393R, Q396R, and R429A) at the LBD of the nuclear receptor
TRß1 cloned into pCMV mammalian expression vector plas-
mid. The presence of the mutations was verified by DNA se-
quencing. The conservation of the TR and TR LBDs is high,
and these mutated residues are conserved (3).
For transactivation assays, U2-OS cells were seeded into 24-
well plates at density of 1  105cells/well and grown in 10%
FBS-DMEMsupplementedwith 2mMglutamine and 50g/mL
streptomycin under 95% air and 5% CO2 at 37°C overnight.
The cells were then cotransfected with 10 ng of pCMV-TR1 or
mutants and with 100 ng thyroid response element (DR4 or
F2)-linked luciferase reporters. The plasmid pRL containing the
Renilla luciferase gene was transfected simultaneously acting as
the transfection control. TransFectin Lipid Reagent (Bio-Rad
Laboratories) was mixed with plasmids in DMEM and incu-
bated at room temperature for 20minutes prior to adding to the
culture media. The ratio of DNA (micrograms) to TransFectin
(microliters) was 1:3. T3 or T4 was added to the culture media 4
hours later and incubated with the cells overnight. The cell
monolayer was then washed with PBS and harvested with lysis
buffer (Dual-Luciferase Report Assay system; Promega Corp.),
following the manufacturer’s instructions. Luciferase activity of
the cell lysate was determined using the Luciferase Assay System
(Promega) and measured in a Safire (2) luminescent counter
(Tecan; Tecan US). TheRenilla luciferase activity was measured
using the same cell lysate (Dual-Luciferase Report Assay system;
Promega) functioning as an internal control for the correspond-
ing luciferase activity to adjust variation caused by transfection
efficiencies (51).
Molecular dynamic simulations
The initial configurations for TR LBD complex were ob-
tained from crystallographic structures reported here (with T3
and T4 in the second binding site) and from Protein Data Bank
(PDB code 3GWS; without ligand in the second binding site).
The complete simulated systems were built with Packmol (52,
53) containing the TR LBD complex, water, and one counte-
rion for each charged residue for electroneutrality (42 Na and
30 Cl ions). We used a cubic box with 16 600 water molecules
with side dimension of 81 Å, leading to a 15 Å hydration layer
in average. A time-step of 2.0 fsec and the velocity Verlet algo-
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rithm (54) were used. A 14-Å cutoff with smooth switching
function starting at 12 Å was applied for the Lennard-Jones
interactions, whereas electrostatic forces were treated via the
particle mesh Ewald summethod (55). Minimization and equil-
ibration were performed as follows. The energy of the system
was minimized by 700 conjugate gradient (CG) steps, keeping
all protein atoms fixed. Fixing only the C atoms, another 500
CG steps were performed. Finally 300CG steps were carried out
without any restrictions. After minimization, 2 nsec equilibra-
tion MD simulations were performed under constant tempera-
ture and pressure conditions (298 K and 1 bar), with Langevin
thermostat and barostat. The damping coefficient of Langevin
thermostat was 5 psec1. The oscillation period and decay time
of the piston in Langevin barostat was 200 fsec and 100 fsec,
respectively. The production MD simulations at constant tem-
perature and pressure were performed after this protocol, last-
ing 6 nsec.
These procedures were repeated 6 times for each of the fol-
lowing systems: 1) TR LBDwith T3 in first and second binding
sites (TR-T3-T3); 2) TR LBD bound to T3 and T4, respec-
tively in the first and in the second binding site (TR-T3-T4); 3)
TR LBD without any ligand in second binding site (TR-T3).
AuxiliaryMD simulationswere performedwith another system:
TR-T3 with tyrosine amino acid bound to the second binding
site (TR-T3-TYR). Tyrosine is a precursor to thyroid hor-
mones, thus having a similar molecular structure. Furthermore,
this amino acid has plasma and intracellular concentration
higher than the thyroid hormones. These features suggest TYR
as a possible natural ligand of the second binding site. The same
procedures described above were used to test this hypothesis,
but with 2 nsec production MD simulations.
All simulations were performed with NAMD 2.7 (56), ap-
plying the CHARMM 27 force field for proteins (57) and the
TIP3P model for water (58). The ligands (T3 and T4) were pa-
rameterized in order to describe the molecular geometry, theo-
retical and experimental torsional barriers (59, 60), and the
partial atomic charges in water solution, following a similar
protocol used for other biomolecules (21, 61, 62).
Free energy calculations
To investigate the binding free energy of T3 and T4 to the
second binding site, the order parameter (or “reaction coordi-
nate”) was chosen as the distance (r) separating the center of
mass of the ligand from a dummy atom placed within the bulk
solution. Rotations and translations of the LBDwere avoided by
applying soft harmonic potentials to all-carbons 20Å from the
second binding site residues.
The dependence of the free energy with ligand displacement
(the G(r) or potential of mean force [PMF]), from 0 to 15 Å
relative to the reference-bound position, was determined using
the Adaptive Biasing Force (ABF) method, implemented in
NAMD (63, 64). The initial structure of the protein was ob-
tained from the last step of one of the equilibrium MD simula-
tions described above. A cubic boxwith 18 600watermolecules
with side dimensions of 97  76  80 Å was used. Instanta-
neous values of the force were accrued in bins 0.1 Å wide.
Boundary potentials with a force constant of 10 kcal/mol/Å2
were also used. These parameters appear to constitute reason-
able choices in other free energy calculations using the ABF
method (63–65). For each system (TR-T3-T3 and TR-T3-T4),
2 simulations were done initially: 1) 25 nsec ABF simulation
with a minimum number of steps sampled (Nsamples) collected
before the full application of ABF force; and 2) 40 nsec ABF
simulation with Nsamples  10 000.
No substantial change was observed in the final values ofG
obtained with different Nsamples used. However, differences
were noted in some regions of PMF curves. To enhance sam-
pling in these regions, three additional 20 ns ABF simulations
with Nsamples 2000 were made for each system in 3 intervals:
0 r 3 Å; 2.5 r 6.5 Å; and 6 r 11 Å. The PMF curve
of each system was calculated as the average of the 5 simula-
tions. The average was done by weighting the samples of the
dG/dr from each bin of the simulations.
Results
Thyroid hormones can bind to a second binding
site on the surface of TR
The structures of the TR LBD in complexwith T3 and
T4 exhibited the classical 3-layered -helical sandwich
conformation, composed of 12 -helices, H1–H12 and 4
short -strands, S1–S4 similar to other TR and - struc-
tures (4, 5, 66, 67). Cocrystallization of TRwith T3 and
T4 yielded structures with good geometric and crystallo-
graphic parameters. The Ramachandran plots were ac-
ceptable for both structures, and no residues were ob-
served in the disallowed region of the plots. The crystals
contained one single TR molecule in the asymmetric unit
organized in the orthorhombic form (Table 1). In each
structure, 2 molecules of hormones per TR were ob-
served in the electron density. For both complex struc-
tures, 1molecule of hormone is located in the LBP and the
other one is found in a second binding site, clearly indi-
cated by the electron density map, located between helix
H9, H10, and H11 (Figure 1 and Figure 2). In the case of
the LBD structure of TR-T3-T3, the coordinates of the
iodine atoms in both binding sites were confirmed with
the use of anomalousmaps composedwith the refinement
phases and anomalous signal from the iodine atoms. In
the structure TR-T3-T4, anomalous maps confirmed the
presence of 4 iodines in the second binding site and 3
iodines in the canonical binding site. Interestingly, in the
latter, indication of the presence of a fourth iodine atom
was obtained with a signal/noise approximately 10 times
lower then the iodine with the highest occupancy. At-
tempts to refine this fourth iodine were unsuccessful.
In the LBP, the ligand is completely enclosedwithin the
core of the LBD and exhibits a similar binding mode, as
described in other TR-T3 and TR-T4 structures (5, 66).
The thyroid hormones interact with the LBP by a hydro-
gen bond between a hydroxyl group and H381, a hydro-
gen bond between a carboxyl group and R228 and, also,
by hydrophobic contacts of thyronine rings and apolar
residues. The difference is that R228 seems to present an
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alternative conformation in the structure when T3 is pres-
ent in the second binding site (discussed below).
In the second binding site, T3 and T4 interact with the
protein mainly by polar interactions between residues
Q342 (located in the helix H10, Q396 in TR1) and
R375 (located in helix H11, R429 in TR1) and apolar
interactions with S326, V371, T372, L346, and L368
(Figure 2). The carboxylic head of the ligand points to-
ward residue R375, whereas Q342 establishes a salt
bridge between its amide group and T3 amino and car-
boxylic groups. Hydrophobic residues between helices
H9 and H10 also create an appropriate surface for ligand
positioning.
TR and TR canonical LBPs differ by a single residue
(Ser277 in TR and Asn331 in TR). However, the main
residues responsible for ligand interaction with the sec-
ond binding site are conserved. Thus, a second T3 or T4
might also bind to TR. Borngraeber et al (68) previously
observed electron density for a second GC-24molecule in
the potential dimerization interface of TR. This result
was considered a crystallization artifact, and the elec-
tronic density was modeled in the pocket formed by heli-
ces H1, H2, H8, andH9.We refined the structure placing
the GC-24 in the crystallographic symmetric position,
which corresponds approximately to the second site pro-
posed here. The final model has an Rfactor and Rfree that
converged at 0.218 and 0.250, respectively. Supplemental
Figure 1, published on The Endocrine Society’s Journals
Table 1. Crystallographic Information: TR in Complex with T3 and T4
Data Collection TR-T3,T3 Complex TR-T3,T4 Complex
Space group P212121 P212121
Unit cell parameters
a (A°) 59.78 59.74
b (A°) 80.79 80.92
c (A°) 102.56 101.87
ASU content (molecules) 1 1
Resolution range (A°)a 63.246  1.90 (2.00  1.90) 63.246  2.05 (2.16  2.05)
Unique reflections 39 906 31 309
Wavelength (Å) 1.5418 1.5418
Multiplicity a 8.0 (8.0) 14.6 (14.9)
Completeness (%)a 99.9 (99.9) 98.9 (97.6)
Rmerge (%)
a,b 0.051 (0.349) 0.068 (0.375)
Mean I/(I) a 25.6 (4.9) 31.8 (6.9)
Bfactor from Wilson plot (Å2) 28.62 30.00
Refinement Statistics
Rfactor
c/Rfree
d 0.1582/0.1843 0.1553/0.1773
RMSD from ideality
Bond lengths (Å) 0.009 0.010
Bond angles (°) 1.321 1.375
Ramachandran analysis
In preferred regions (%) 96.55 97.11
In allowed regions (%) 3.45 2.89
Outliers (%) 0 0
PDB code 4LNW 4LNX
Abbreviation: ASU, asymmetric unit; RMSD, root mean square deviation.
a Values in parameters refer to the last resolution shell.
b Rmerge: hkl,j ( Ihkl  Ihkl )/hkl,j Ihkl, where Ihkl is the average intensity for a set of j symmetry-related reflections, and Ihkl is the value of the
intensity for a single reflection within a set of symmetry-related reflections.
c Rfactor: hkl ( Fo  Fc )/hkl Fo , where Fo is the observed structure factor amplitude, and Fc is the calculated structure factor amplitude.
d Rfree: hkl,T( Fo  Fc )/hkl Fo , where a test set, T (5% of data), is omitted from the refinement
Figure 1. Crystal structure of TR LBD complexes. A, The overall
structure of TR with two T3 molecules bound. The T3 bound to the
second binding site is located in the upper part. B, The overall structure
of TR with T3 and T4 molecules bound. The T4 bound to the second
binding site is located in the upper part between helix H9, H10, and
H11. H12 is in blue in both structures.
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Online web site at http://mend.endojournals.org, shows
GC-24 bound to the second binding site in TR. The phe-
nol group of the second GC-24 molecule interacts with
Q396 in H10, which corresponds to residue Q342 in
TR, resembling the interaction of T3 and T4 in the sec-
ond binding site observed in our structures.
Residues of the second binding site are coupled
with relevant function regions and are important
for transactivation of the TR
Statistical coupling analysis (SCA) was already shown to
be an efficient technique to identify the positions that have
been functionally constrainedduring evolution.Herewe an-
alyzed a multiple alignment of the NR’s LBD looking for
statistical couplings involving the residues interacting with
the second binding site. If 2 positions have high Gstat,
these positions suffered correlated mutations during evolu-
tion, which can reveal functional correlations within sub-
structures of the protein (49, 50). An analysis of Gstat
computed from our sequence alignment revealed a number
of coupled positions, shown in a matrix form in Figure 3.
The TR residues Q342, E339, and R375 that make polar
contacts with T3 and T4 in the second binding site show
coupling with each other and with several positions identi-
fied by SCA, such as R266 (LBP) and
L374 (H11-dimerization interface).
Moreover, residues Q342, E339, and
R375 are also coupled to amino acids
located at the hydrophobic groove, re-
sponsible for interactions with co-
regulators (A233 and K234, at H3;
F239 at H5; Q247 and K252, at H5);
position L400 (H12), and the charge
clamp residues K234 and E403, in-
volved inactivation function2 (AF-2).
These results indicate that residues
making up the second binding site
could be important for allosteric
mechanism.
Our analyses also indicated a reg-
ulatory role of the second site on the
TR activity, as shown for F2- and
DR4-dependent reporters in Figure
Figure 2. Electron density map of a second bound T3 and T4 in TR receptor. A, Electron density map and polar interactions of T3. B, Electron density
map and polar interactions of T4. A -weighted 2 Fo-Fc omit electron-density map is shown contoured at 1.0  for the area surrounding the T3 and T4
ligands. The T3 and T4 are colored by element. The amino acid residues that interact with the ligands are labeled and displayed as sticks.
Figure 3. Matrix of Gstat values reporting coevolution of many pairs of positions in an
alignment of 1237 members of the NR_LBD family after cluster analysis. Rows in the matrix
represent LBD positions and columns represent perturbations. The color scale ranges from white
for small Gstat values to dark red for high Gstat values. The residues of the TR second
binding site are highlighted in the graph axes.
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4. For example, T3 dose-response curves at the F2-depen-
dent reporter show that the mutant R429A, in which the
arginine that interacts to the carboxylate portion of li-
gands is substituted by an alanine, exhibits just 35% of
wild-type TR1 maximum response. Likewise, E393R
and Q396R mutations also exhibit reduced transcrip-
tional activity (50% and 25%, respectively). In contrast,
the mutant D382R, in which one of the aspartic acids that
makes a salt bridge with T3 is changed to arginine, exhib-
ited an increase in transcriptional response (212% of the
maximumwild-type TR1 activity). The results obtained
for T3 at DR4 and T4 at F2 exhibit the same trends.
MD simulations show a mobile and high-affinity
second binding site
MD simulations of 3 different systems were per-
formed: TR LBD bound with T3 in the second binding
site (TR-T3-T3), TR LBD bound with T4 in the second
binding site (TR-T3-T4), and TR LBD without ligand
in the second binding site (TR-T3).
The results of these simulations show that T4 is less
mobile than T3 in the second binding site (Figure 5, A, B,
and D), but both have high mobility compared with T3 in
the LBP (Figure 5C). The phenolic ring is the most mobile
part of T3 or T4 in the second binding site. Unlike in the
LBP, the phenol group of the hormones does not make
polar interactions with the LBD.
The LBD-ligand interaction energies reflect the high
mobility of ligands on the second binding site, denounc-
ing the existence of multiple binding modes (Figure 6, A
and C), hereafter denoted as strong mode (I), dynamic
mode (II), and weak mode (III). The main residues that
interact with ligands on the second site are E339, Q342,
and R375 (TR, Figure 6B). In addition to these, smaller
contributions come from the negatively charged residues
D328, D336, and E343. Additionally, there is a large
fluctuation of the D328-ligand interaction energy, which
can even result in unfavorable (positive) interactions.
T4, which is less mobile than T3 in the second binding
site, does not display the weak mode, and the interaction
energies of the dynamicmode aremore favorable than the
T3 ones (Figure 6A). We believe that this is because T4 is
more hydrophobic, thus improving its attachment to the
LBD. On average, the LBD-ligand interaction energies of
T4 and T3 in the second binding site are 150.70 and
120.6 kcal.mol1, respectively. These interaction ener-
gies indicate that T4 has higher affinity than T3 to the
second binding site.
Because the measurement of TR-ligand affinity in the
second binding site is essential to verify the possibility of
this site actually existing in physiologic solution, we per-
formed extensive MD simulations (	125 nsec for each
system) using the ABFmethod to obtain an estimate of the
binding free energy of each ligand. Figure 6D shows the
free-energy profile corresponding to the dissociation of
the ligand. The free-energy difference between ligand
bound and unbound states obtained for T3 and T4 was
G  9.6 and 14.2 kcal.mol1, respectively. These
Figure 4. TR1/luciferase transactivation assays of T3 and T4 doses at
F2 and DR4 response element-dependent reporters. The cells are
transfected with wild-type TR1 and single-point mutations in residues
of the second binding site (D382R, E393R, Q396R, and R429A). The
activities are expressed relative to the maximum response of the wild-
type (concentration of 106 M to T3 and 10
5 M to T4), which is set to
100%. Error bars represent the SDs of at least 4 experiments, being
featured only values above 4%.
Figure 5. MD simulations show a high mobility of the ligands in
second binding site. The first two pictures show the superposed
configurations and the corresponding average occupied volume of T3
(A) and T4 (B) in the second binding site. The same analysis for T3 in
the first binding site is shown in panel C. T4 is less mobile than T3 in
second binding site, and both are more mobile than T3 in the first
binding site. Distributions of root mean square deviation (RMSD) (D) of
natural ligands in the first and in the second binding sites show
quantitatively the results presented in the previous figures.
Interestingly, T3 is more mobile in the first binding site when there is a
ligands bound to the second site.
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correspond to binding affinities (Kd) of 90.9 nM for T3
and 0.04 nM for T4. These results are consistent with
observations from equilibrium MD simulations, which
already indicated that T4 has greater affinity than T3 for
the second site.
Other biomolecules present in higher concentrations
could also be potential second-site ligands. AuxiliaryMD
simulations were performed to evaluate the possibility of
the amino acid tyrosine acting as a ligand for the second
binding site, but tyrosine does not display a stable attach-
ment to the site and dissociated from it in all simulations
(Supplemental Figure 2).
Influence of the second site in the structure,
dynamics, and interactions of the first site
Binding of T3/T4 to the second binding site may be
associated with alterations of the structure and dynamic
behavior of the LBD. Our equilibrium MD simulations
did not show any significant differ-
ences in backbone mobility. How-
ever, we observed that the ligand in
the LBP has a slightly higher mobil-
ity when the ligand is present in the
second binding site, as shown by the
root mean square deviation peaks in
Figure 5D. The average interaction
energies also show that the interac-
tions of T3 in the first binding site
with the protein are less favorable
when a ligand is bound to the second
site: 124.2 kcal.mol1 for TR-
T3;113.8 kcal.mol
1 for TR-T3-
T3; and 116.2 kcal.mol
1 for
TR-T3-T4.
These changes are related to the
reduced interactions of T3 with
R228, one of the main residues in
the LBP that may interact with the
solvent, as indicated by MD simula-
tions of systems containing ligands
in the second binding site. Although
infrequent, this change in the side-
chain position is consistent with the
2 conformations of R228 observed
in the crystallographic structure
with T3 in the second binding site
(Figure 7). In the TR crystallo-
graphic structure with T4 in the sec-
ond site, this alternative electron
density seems to be better fitted by a
water molecule in this region. How-
ever, the possibility of a second
R228 conformation cannot be ruled
out in this case also. These results indicate that ligands on
the second binding site may influence ligand-protein in-
teractions in the LBP.
Discussion
In this study, we used X-ray crystallography to obtain
new structures of the TR LBD associated with the nat-
ural thyroid hormones, T3 and T4. Surprisingly, we ob-
served 2 ligand molecules associated with the TR LBD,
one anchored to the conventional LBP and another in a
new second binding site, located on the surface of the
protein, between H9, H10, and H11. Except for the sec-
ond hormonemolecule, the structure appears very similar
to other TR LBDs associated with agonist ligands, in
which H12 is in appropriate position for interaction with
Figure 6. Multiple binding modes of the ligands in the new site and estimates of the Gbinding.
A, Distributions of the LBD-ligand interaction energy of T3 (black) and T4 (red) in the second
binding site. B, Average interaction energy between the ligands and principal residues in the
second binding mode. C, The multiple binding modes of T3 and its complex interconversion. T3
clearly shows 3 binding modes with different interaction energies: strong mode (I), dynamic
mode (II), and weak mode (III). D, The free energy change (or PMF) for the ligand dissociation of
the second binding site obtained by Adaptative Biasing Force (ABF) method. The final Gbinding
of T3 and T4 was approximately 9.5 and 14.2 kcal.mol
1, respectively.
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coactivators (4, 5, 66, 67). Until now, this second binding
site had never been reported for other NR structures.
However, the structure refinement of TR1 LBD associ-
ated with two GC-24 molecules, one of them on the sym-
metrical position, shows the existence of a second binding
site at another crystallographic NR structure, already
available in the literature, but apparently not previously
noticed.
MD simulations confirm the structural observations
and clearly show that the main polar interactions of T3
and T4 in the second site involve Q342 and R375 resi-
dues. These features make the second binding site similar
to LBP of TRs, especially the TR, in which the ligand
also interacts with an arginine and a glutamine. However,
there are some striking differences between the sites. The
second binding site is less hydrophobic and more solvent
is exposed in both TR structures than in the first binding
site. Another difference between the 2 sites is the presence
of negatively charged residues D328, D336, E339, and
E343 (D382, E390, E393, and D397 in TR1) near to the
amino group of T3 and T4, where the interaction can be
intermediated by water molecules. The LBP does not
show any negatively charged residue in its cavity but
shows positively charged residues (R228, R262, and
R266 in TR; R282, R316 and R320, in TR1).
It is also important to remark that the ligand is in a
different conformation in the second binding site. Previ-
ous NMR studies of thyroid hormones in aqueous solu-
tions show that there are 2 major conformations of T3
and T4 in water: cisoid and transoid (59, 60). When
bound to TRs, T3 and T4 assume only one conformation,
depending on the binding site: transoid in the LBP and
cisoid in the new second binding site. The conversion
between the 2 conformations in water occurs in the mi-
crosecond time scale (59) and may influence the associa-
tion mechanisms and kinetics of the ligands in the differ-
ent binding sites. Finally, our results also highlight the
increased mobility of ligands at the second binding site in
relation to T3 in the LBP. The greater mobility of ligands
bound to proteins can be an important factor to deter-
mine the affinity and/or selectivity for specific binding
sites, as demonstrated by the entropic gain of Triac ligand
in TR1 LBP (8).
These differences in the ligands’ conformation, mobil-
ity, hydration, and interactions with the LBD can be used
for the rational design of drugs that are selective for dif-
ferent TR binding sites. However, prior to this, a better
understanding of the affinity and biological function of
the natural ligands on the second binding site is necessary.
The present study is a first step toward this goal.
MD simulation estimates of thyroid hormones affini-
ties for the second site suggest T4 as a strong candidate for
the natural high-affinity ligand of the second biding site
under physiologic conditions. The range of serum and
intracellular concentrations of the thyroid hormones (69,
70) also strengthens this hypothesis. However, T3 should
not be discarded as a second-site binder for several rea-
sons: the intracellular concentration of T3 is usually
greater than its plasma concentration (69, 70); the heter-
ogeneity of T3 concentration in cellular compartments
(71), particularly cell nucleus; and the small amount of
TR molecules (2,000–10 000) in the cell nucleus (72),
which can facilitate the saturation of the LBD binding
sites, even at low concentrations of T3.
Our SCA results and mutant transactivation assays sup-
port the existence of a functional networkof residues involv-
ing the second binding site identified in our crystal structure
and other important regions of the LBDs. However, these
results do not rule out possible effects caused by these mu-
tations directly in the LBP or their effect in coregulator re-
cruitment and dimerization, or even partial structure desta-
bilization. Indeed, previous studies indicate that mutations
relatively distant from the canonical binding site can affect
ligand interactions with LBP (73). TR mutations in the
correspondent residuesR429andQ396 (R375andQ342 in
TR) caused weak and stronger decreases in nuclear recep-
tor corepressor binding, respectively. In fact, these residues
were characterized as “Site 3” for corepressor binding (74).
Furthermore, H10 and H11 participate in the formation of
TR-TR homodimerization (75) and TR-retinoid X receptor
heterodimerization surfaces (76, 77). Thus, a second mole-
cule bound in this region could influence dimer formation.
The double conformation of R228 observed in the
crystal structures and MD simulations suggest that li-
gands in the second binding site can influence ligand-
protein interactions in the LBP. It is well established that
R228 of TR (R282 in TR1) is very important for ligand
affinity and selectivity (77). Furthermore, this residue is
involved in the dissociation path III, which, according to
Figure 7. Two conformations of R228, one of the main residues in
the cognate binding site, observed in the crystallographic structure
with T3 in the second binding site. A, R228 exposed to the solvent and
(B) interacting with the ligand. MD simulations also reveal these 2
conformations.
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MD simulations, is likely the main ligand exit route from
TR LBD (20, 21). Thus, this double conformation may
reduce the ligand affinity to and/or facilitate its dissocia-
tion from the LBP. In fact, it has been shown that certain
ligands, such as GC-24 and T4, can accelerate the disso-
ciation of T3 from the LBP. These results were explained
by the hypothesis of these ligands anchoring to some dif-
ferent region of LBD, facilitating the dissociation of T3
from the LBP (14). One possibility is that this different
region is the second binding site that we report here.
Another curious fact is that the second binding site is
located exactly in the same region where the F domain
may dock. F domain is an extension to the C terminus of
H12 present in some of the NRs, with an unknown func-
tional role. There is no F domain in human TRs. How-
ever, it has been recently found that a TR isoform from
zebrafish does have an F domain (78). Although the struc-
ture is unknown, functional assays reveal that the pres-
ence of the F domain represses transcriptional activity and
reduces the ability to recruit certain coactivators (78).
Supplemental Figure 3 shows the LBD structures of the
androgen and thyroid receptors aligned, highlighting the
F domain of AR and T3 in the second binding site of TR.
The similarity between the positions where the F domain
is docked and the second binding site is remarkable. This
coincident position suggests a common function for this
region: to modulate transcriptional repression.
Thus, it is possible to speculate that the TR’s activation
may be suppressed by high concentration of the thyroid
hormones in the nucleus cell. The excess of hormones
leads their association to the second binding site. This
could induce ligand dissociation from the LBP (responsi-
ble for agonist conformation of H12), thereby reducing
gene transcription. Experimental evidence of these ideas
was sought after by our group, but technical difficulties
prevented us from obtaining reliable results. If this hy-
pothesis proves correct, binding to the second site could
be a mechanism to prevent superactivation of TRs, de-
pending on the concentration of ligands.
In summary, the results presented here show a new
binding site of the natural thyroid hormones in the TR’s
LBD. They also indicate that this second binding site may
modulate changes in activity and interaction with ligands
in the LBP. Nevertheless, binding of a molecule to a sec-
ond binding site could be useful as a new target for TR
drug design and could selectively modulate NR functions.
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